Interleukin-2 Stimulated T-Lymphocyte Cell Death for the Treatment of Autoimmune Diseases, Allergic Disorders and Graft Rejection

T-cell apoptosis induced by administration of IL-2 and antigen offers an important new treatment for allergic disorders, which are due to the effects of antigen-activated T-cells. Antigen-activated T-cells cause the release of harmful lymphokines and the production of immunoglobulin E by B cells. Presently available methods for treating allergies have limitations because they are nonspecific in their action and have side effects and limited efficacy. IL-2 and antigen stimulates the programmed death of only antigen-specific T-cells while leaving the rest of the patient's T-cells and other immune cells intact. This invention is also useful in treating HIV. Both fields of use, allergies and HIV, are available for licensing.

Potential Commercial Applications:		Competitive Advantages:
allergies HIV complications		precise for a specified antigen does not compromise a patient's immune system

Inventors:

Michael Lenardo (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 6,083,503 issued 2000-07-04
U.S. Pat: 5,989,546 issued 1999-11-23
US Application No. 07/751,090
PCT Application No. PCT/US93/005481

Publications:
Racke MK, et al. PMID 8572666
Critchfield JM, Lenardo MJ. PMID 7882590
McFarland HI, et al. PMID 8644500
Critchfield JM, et al. PMID 7509084

Licensing Contact:
Yogikala Prabhu,
Email: prabhuyo@niaid.nih.gov
Phone: 301-761-7789

OTT Reference No: E-137-1991-0
Updated: Nov 2, 2015